白细胞介素-7诱发皮肤T细胞淋巴瘤细胞JAK-3的磷酸化和活化  

Induced phosphorylation and activation of JAK 3 in CTCL cells by interleukin 7

作　　者：董子明[1,2] 杨洪艳 张义国[1,2] 赵明耀 郑智敏[1,2] 

机构地区：[1]河南医科大学病理生理学教研室 [2]耶鲁大学医学院皮肤系

出　　处：《河南医科大学学报》1999年第1期14-18,共5页Journal of Henan Medical University

摘　　要：目的：ＩＬ７可刺激一些良性和恶性淋巴细胞增生，其中包括来自皮肤样Ｔ细胞瘤（ＣＴＣＬ）病人的肿瘤细胞。Ｊａｎｕｓ激酶家族（ＪＡＫｓ）与许多细胞因子受体的信号传导系统有关。ＪＡＫ３是ＪＡＫｓ激酶家族的新成员，其在自然杀伤细胞（ＮＫ）和活化的Ｔ细胞上表达，并在这些细胞中从功能上和物理上与白细胞介素２受体（ＩＬ２Ｒ）结合起来。为此，本研究进一步探讨白细胞介素７（ＩＬ７）引起皮肤样Ｔ细胞瘤肿瘤细胞ＪＡＫ３的磷酸化和活化。方法：ＣＴＣＬ外周血中分离的肿瘤细胞，用ＩＬ７分别处理１、５、１０、２０ｍｉｎ，蛋白裂解物用抗ＪＡＫ３抗体，抗ｐ５９ｆｙｎ抗体进行免疫沉淀，用抗ＪＡＫ３和抗磷酸化酪氨酸作Ｗｅｓｔｅｒｎ印迹检测。结果：ＩＬ７能引起ＣＴＣＬ肿瘤细胞的ＪＡＫ３酪氨酸磷酸化，抗ｐ５９ｆｙｎ抗体能结合ＪＡＫ３，未发现ＩＬ１２能诱导ＣＴＣＬ细胞的ＪＡＫ３磷酸化。结论：提示ＩＬ７可能在ＣＴＣＬ的病理生理学上起一定的作用，且证实在ＣＴＣＬ细胞中ＩＬ７受体介导了酪氨酸磷酸化的信号传导途径。Aim: To study induced phosphorylation and activation of JAK 3 in cutaneous T cell lymphoma (CTCL) by interleukin 7 (IL 7).IL 7 stimulates proliferation of several benign and malignant lymphocyte populations including tumor cells from patients with CTCL.The Janus family of kinases (JAKs) has been shown to be involved in the signal transduction of a number of cytokine receptors.A novel JAK family member JAK 3,which is expressed in natural killer (NK) and activated T cells,is coupled functionally and physically with the interleukin 2 (IL 2) receptor (IL 2R) in those cells.Methods:Cells isolated from peripheral blood of CTCL patients were treated with IL 7 in vitro for 1,5,10,15 and 20 min,respectively.Immunoprecipitating the lysates was performed with anti JAK 3 andanti p59fyn antibodies and Western blotting with anti phosphorylated tyrosine and anti JAK 3 antibodies.Results:IL 7 induced tyrosine phosphorylation of JAK 3 in CTCL cells.Anti p59fyn antibody co immunoprecipitated with JAK 3.But it was not found that IL 12 could induce phosphorylation of JAK 3.Conclusion: These results suggest that lL 7 may play a role in pathophysiology of CTCL,and indicate that the IL 7 receptor (IL 7R) mediates the activation of the tyrosine phosphorylation signal transduction pathway.

关 键 词：信号传导 皮肤肿瘤 CTCL IL-7 JAK-3 磷酸化 

分 类 号：R739.502[医药卫生—肿瘤]